Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug

Surgical Infections

Volumn 14, Issue 5, 2013, Pages 455-459

  Stitely, Michael ^a   Sweet, Michael ^b   Slain, Douglas ^b   Alons, Lindsy ^c   Holls, William ^c   Hochberg, Charles ^c   Briggs, Frank ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN;

ADULT; ARTICLE; BODY MASS; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG TISSUE LEVEL; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; INCISION; MINIMUM INHIBITORY CONCENTRATION; MORPHOMETRICS; MYOMETRIUM; OBESITY; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS TISSUE; SURGICAL INFECTION; UMBILICAL CORD; UTERUS BIOPSY; WOUND CLOSURE;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEFAZOLIN; CESAREAN SECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MYOMETRIUM; OBESITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREOPERATIVE CARE; SURGICAL WOUND INFECTION; UMBILICAL CORD;

EID: 84887866683     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2012.040     Document Type: Article

References (23)

1. Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189:395-404.
2. Tita AT, Rouse DJ, Blackwell S, et al. Emerging concepts in antibiotic prophylaxis for cesarean delivery: A systematic review. Obstet Gynecol 2009;113:675-682.
3. Olsen MA, Butler AM, Willers DM, et al. Risk factors for surgical site infection after low transverse cesarean section. Infect Control Hosp Epidemiol 2008;29:477-484.
4. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation. Ninth edition. Philadelphia. Lippincott, Williams & Wilkins, 2011.
5. The American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Committee opinion no. 465: Antimicrobial prophylaxis for cesarean delivery: Timing of administration. Obstet Gynecol 2010;116:791-792.
6. Killian CA, Graffunder EM, Vinciguerra TJ, et al. Risk factors for surgical-site infections following cesarean section. Infect Control Hosp Epidemiol 2001;22:613-617.
7. Johnson A, Young D, Reilly J. Caesarean section surgical site infection surveillance. J Hosp Infect 2006;64:30-35.
8. Ward VP, Charlett A, Fagan J, Crawshaw SC. Enhanced surgical site infection surveillance following caesarean section: Experience of a multicentre collaborative post-discharge system. J Hosp Infect 2008;70:166-173.
9. Vermillion ST, Lamoutte C, Soper DE, et al. Wound infection after cesarean: Effect of subcutaneous tissue thickness. Obstet Gynecol 2000;95:923-926.
10. Chelmow D, Rodriguez EJ, Sabatini MM. Suture closure of subcutaneous fat and wound disruption after cesarean delivery: A meta-analysis. Obstet Gynecol 2004;103:974-980.
11. Gardella C, Goltra LB, Laschansky E, et al. High-concentration supplemental perioperative oxygen to reduce the incidence of postcesarean surgical site infection: A randomized controlled trial. Obstet Gynecol 2008;112:545-552.
12. Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003;17:599-613.
13. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989;106:750-757.
14. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: Do we achieve therapeutic levels? Surgery 2004;136:738-747.
15. Barbour A, Schimdt S, Rout W, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents 2009;34:231-235.
16. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect 2012;13:33-37.
17. Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011;117:877-882.
18. Horan TC, Andrus ML, Dudeck MA. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332.
19. Performance Standards for Antimicrobial Susceptibility Testing: Twenty Second Informational Supplement. CLSI document M100-S22. Wayne, PA. Clinical and Laboratory Standards Institute, 2012.
20. Farthing C, Farthing D, Brophy DF, et al. High-performance liquid chromatographic determination of cefepime and cefazolin in human plasma and dialysate. Chromatographia 2008;67:365-368.
21. Jones RN, Jenkins SG, Hoban DJ, et al. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program 1997-1998. Diag Microbiol Infect Dis 2000;37:93-99.
22. Turnidge JD. Cefazolin and Enterobacteriaceae: Rationale for revised susceptibility testing breakpoints. Clin Infect Dis 2011;52:917-924.
23. Adam D, Patzold J. Serum concentrations and kinetics after intravenous infusion of four grams of cefazolin. Infection 1977;5:228-231.